Floatz logo

DIPLOCOCCUS LANCEOLATUS WHOLE

Small Intestine Cancer

Ohio State University Comprehensive Cancer CentervaccineN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Small Intestine Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
Cancer Research UK
Phase 2BB
VINCRISTINE SULFATE
Cancer Research UK
Phase 2BB
FILGRASTIM
Cancer Research UK
Phase 2BB
Carboplatin
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

DIPLOCOCCUS LANCEOLATUS WHOLE is also rated in:

plasma cell myelomaDormant
D
Indicative ·
30 / 100
View asset →
lymphomaDormant
D
Indicative ·
28 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →